Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_assertion type Assertion NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_head.
- NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_assertion description "[The rationale of combination of danazol or lenalidomide with ruxolitinib is mainly based on mitigation of anti-JAK2-mediated myelosuppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_provenance.
- NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_assertion evidence source_evidence_literature NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_provenance.
- NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_assertion SIO_000772 25189730 NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_provenance.
- NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_assertion wasDerivedFrom befree-2016 NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_provenance.
- NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_assertion wasGeneratedBy ECO_0000203 NP1217014.RAFNCrZ5BzlwNzZ7ausv0mQ4keUuhfiTYOCToxD_euhOs130_provenance.